Bottom line
Is LABD a good fund? The bottom line
LABD is an index leveraged & inverse ETF from Direxion.
It charges 1.07% — about $107 a year on every $10,000 invested, cheaper than 64% of leveraged & inverse funds we track.
It returned −70.0% over one year, −37.7% a year over five years, −54.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $54.2 million in net assets and 10 holdings, its largest position is Goldman Financial (52.7%) and the top 10 make up 125% of the portfolio.
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 125% of assets
Updated Nov 19, 2026
What LABD invests in
The Fund seeks daily investment results, before fees and expenses, of 300% of the inverse (or opposite) of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). GICS classifications are determined primarily based on a companys revenues, however, earnings and market perception are also considered by GICS. The Index consists of constituents of the S&P Total Market Index (S&P TMI) that belong to the GICS biotechnology sub-industry that satisfy the following criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%…
From the fund's prospectus (filed Mar 3, 2026).
LABD performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LABD | −70.0% | −37.7% | −54.4% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What LABD costs
On a $10,000 investment, LABD's 1.07% expense ratio costs about $107 a year. The prospectus estimates $1,316 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
LABD top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Goldman Financial | 52.74% |
| 2 | Dreyfus | 40.47% |
| 3 | Goldman Sachs Liq Es Fd A | 26.30% |
| 4 | Dreyfus | 18.03% |
| 5 | N/a | 2.98% |
| 6 | N/a | 1.43% |
| 7 | N/a | -1.55% |
| 8 | N/a | -4.11% |
| 9 | N/a | -4.88% |
| 10 | N/a | -6.37% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 125% of the fund. See all top 25 holdings and asset mix →